BIR Chief Personally Seized FLAVA E-cigarette Vending Machine, Encouraging Public Reporting

Regulations by 2FIRSTS.ai
Jul.19.2024
BIR Chief Personally Seized FLAVA E-cigarette Vending Machine, Encouraging Public Reporting
BIR chief personally seizes FLAVA e-cigarette vending machine, raising concerns about illegal products sold near children's facilities.

According to Manila Standard's report on July 18, the Bureau of Internal Revenue (BIR) in the Philippines announced that Director Romeo Lumagui Jr. personally led the seizure of an automated vending machine selling FLAVA brand e-cigarette products. The brand had previously been ordered to cease operations by the agency.

 

According to reports, the closure stemmed from a report by a netizen on the official Lumagui Facebook page.

 

During the raid, it was discovered that FLAVA e-cigarette products were being sold at a price of 500 pesos each ($8.57).

 

The organization stated that the situation is concerning because illegal e-cigarette products are openly being sold in the building, and just steps away from this building are a gym, dance studio, gymnastics studio, basketball court, coffee shop and bakery, laundry, drinking water station, and restaurant. BIR pointed out that children may purchase FLAVA e-cigarettes due to vending machines being accessible to the public.

 

The commissioner stated that

 

Selling illegal e-cigarettes is against the law, whether it is done through vending machines or online stores. BIR will seize and crack down on any illegal e-cigarette products. We would like to thank the individual who reported a vending machine on my official Facebook page approximately two weeks ago. This morning, we sealed the vending machine. BIR welcomes all reports of illegal e-cigarette activities. Rest assured, we will take action against all verified targets.

 

In March 2023, the BIR conducted a raid on a warehouse in Laguna storing illegal FLAVA e-cigarette products. The raid resulted in the seizure of 1,029 large boxes, equivalent to 102,900 e-cigarettes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JUUL wins approval after FDA reversal of Marketing Denial Order
JUUL wins approval after FDA reversal of Marketing Denial Order
JUUL's regulatory journey from Marketing Denial Order to approval showcases FDA's evolving approach to e-cigarette oversight.
Nov.03 by 2FIRSTS.ai
FDA’s Makary on CNN: The Triple Challenge in Vape Regulation — New Opioids, Illicit Trade, and Youth Protection
FDA’s Makary on CNN: The Triple Challenge in Vape Regulation — New Opioids, Illicit Trade, and Youth Protection
In an interview with CNN’s Chasing Life, U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary warned that new health risks — from emerging opioids such as 7-OH to unregulated vaping products — are slipping through regulatory cracks. His remarks reveal the FDA’s growing challenge to balance harm reduction for adult smokers with youth protection and cross-border enforcement.
Oct.10
China Tobacco Hunan IC × Firstunion Group: Usonic Dual Wins International Award with Omni-directional Thermal Technology
China Tobacco Hunan IC × Firstunion Group: Usonic Dual Wins International Award with Omni-directional Thermal Technology
On September 18 at InterTabac 2025, China Tobacco Hunan IC launched the Usonic Dual, NISE, winning the "Best HNB Product Award." Featuring innovative "Omni-directional Vortex Thermal Field" technology and AI interaction, it enhances flavor, efficiency, and user experience, marking a significant advancement in global HTP development driven by Chinese innovation.
Sep.20
Switzerland's Geneva to enforce ban on disposable e-cigarettes following court ruling
Switzerland's Geneva to enforce ban on disposable e-cigarettes following court ruling
The Canton of Geneva has begun enforcing its ban on disposable e-cigarettes (“puffs”) after the cantonal court rejected industry appeals to suspend the law. Passed on August 29 by the Grand Council, the ban will now be actively monitored by trade inspectors, while a similar measure is already in force in Valais.
Nov.07 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
JTI launches Ploom AURA new heated tobacco device device in Romania
JTI launches Ploom AURA new heated tobacco device device in Romania
Japan Tobacco International(JTI) introduces Ploom AURA in Romania, combining SMART HEATFLOW technology to preserve tobacco flavor, aiming at high-end consumers.
Oct.17 by 2FIRSTS.ai